Furthermore, TOP2A expression has been reported to be a valuable prognostic marker for tumor advancements, recurrences, and predictor of poorer survival in small cell lung cancer, ovarian, colon, breast, and prostate cancers, as well as nasopharyngeal carcinoma [41–46]. This evidence concerns the gene TOP2A and small cell lung carcinoma.